Medical Letter on the CDC & FDA
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC & FDA
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Cardiovascular Disease
Rimonabant accepted for filing by the FDA
July 24th, 2005
Sanofi-aventis announced that the United States Food and Drug Administration (FDA) has accepted for filing the company's new drug application (NDA) for rimonabant, the first agent in a new therapeutic class known as selective cannabinoid type 1 (CB1) blockers. Rimonabant, discovered and developed by sanofi-aventis, is thought to represent a new approach for the comprehensive management of cardiovascular risk factors. The compound has been studied to date in over 6,500 overweight and obese adults for up to 2 years. Despite therapeutic advances in recent decades, cardiovascular disease remains the leading cause of mortality worldwide. Current...
Source: Medical Letter on the CDC & FDA (2005-07-24)
|
